

**Supplementary material**

**Table of content**

- (A) Section: Questionnaire for study participants..... 2
- (B) Section: System Usability Scale (SUS) ..... 5
- (C) Section: Ease-of-Use Assessment (EoU) ..... 6
- (D) Figure 1: Matrix for Ease-of-Use Assessment ..... 17
- (E) Table 1: Detailed list of symptoms for all PCR positives ..... 19
- (F) Table 2: Antigen-based RDT with test result, CT values and viral load for PCR positive participants in Berlin and Heidelberg ..... 24
- (G) Figure 2: Correlation between the cut-off-index value and the viral load for all RT-PCR positive cases... .....28
- (H) Table 3: Discrepant analysis..... 29
- (I) Table 4: Exclusivity testing of LumiraDx™ ..... 31
- (J) Figure 3: System Usability Score and Ease-of-Use assessment results..... 32
- (K) Table 5: Comorbidities and list of symptoms of participants overall, Berlin and Heidelberg 33
- (L) Table 6: Sensitivity and Specificity overall and by subgroups ..... 34

## (A) Section: Questionnaire for study participants

We invite you to participate in this survey. The survey serves to understand the diagnostic process and the disease and factors related to SARS-CoV-2 (novel coronavirus) infection.

Your answers will be kept strictly confidential and will not have a negative impact on your care. Participation in the study is voluntary and you have the option to skip questions that you do not want to answer.

The survey is expected to take 15-20 minutes. Thank you for your understanding and cooperation!

Postal code	<i>(Free text)</i>
Gender	<input type="radio"/> Male <input type="radio"/> Female <input type="radio"/> Diverse
How tall are you (in centimetres)?	<i>(Free text)</i>
How much do you weight (in kilograms)?	<i>(Free text)</i>

### Symptoms that you attribute to the possible COVID-19

Did you have any symptoms of possible COVID-19 on the day of the test?	<input type="radio"/> No <input type="radio"/> Yes
Increased temperature / fever?	<input type="radio"/> No <input type="radio"/> Yes
Did you measure your fever?	<input type="radio"/> No <input type="radio"/> Yes
Highest temperature (in Celsius)	<i>(Free text)</i>
Cough	<input type="radio"/> No <input type="radio"/> Yes
Do you have a productive cough?	<input type="radio"/> No <input type="radio"/> Yes
Sore throat	<input type="radio"/> No <input type="radio"/> Yes
Shortness of breath	<input type="radio"/> No <input type="radio"/> Yes
Muscle pain / Body aches	<input type="radio"/> No <input type="radio"/> Yes

Fatigue	<input type="radio"/> No <input type="radio"/> Yes
Headache	<input type="radio"/> No <input type="radio"/> Yes
Runny nose	<input type="radio"/> No <input type="radio"/> Yes
Chest pain	<input type="radio"/> No <input type="radio"/> Yes
Diarrhea	<input type="radio"/> No <input type="radio"/> Yes
Nausea / vomiting	<input type="radio"/> No <input type="radio"/> Yes
Loss of taste or smell	<input type="radio"/> No <input type="radio"/> Yes
Other	<input type="radio"/> No <input type="radio"/> Yes
If yes, please specify	<i>(Free text)</i>
The earliest onset of symptoms attributed to possible COVID-19	<i>(Day / Month / Year)</i>
How sick did you feel on the day of the test?	<input type="radio"/> Normal unrestricted activity as before the illness <input type="radio"/> Restriction with physical exertion, but able to walk; light physical work or work while sitting, e.g., light housework or office work, possible <input type="radio"/> Able to walk, self-sufficiency possible, but not able to work; can get up more than 50% of the waking time <input type="radio"/> Only limited self-sufficiency possible; 50% or more of the waking time tied to bed or chair <input type="radio"/> Completely in the need of care, no self-sufficiency possible; completely tied to bed or chair
Did you previously test negative within the last 10 days?	<input type="radio"/> No <input type="radio"/> Yes
If yes, when	<i>(Day / Month / Year)</i>
If yes, where	<input type="radio"/> University clinic – inpatient <input type="radio"/> University clinic – outpatient <input type="radio"/> Drive-in

	<input type="radio"/> Other
Other, please specify	<i>(Free text)</i>
Do you know where you might have been infected with COVID-19?	<input type="radio"/> Household contact <input type="radio"/> Social contact <input type="radio"/> Work contact <input type="radio"/> Contact in university / school / kindergarten from you or a child in the family <input type="radio"/> Travel to risk area <input type="radio"/> Do not know <input type="radio"/> Other
Risk area	<i>(Free text)</i>
Other: please describe	<i>(Free text)</i>

**Do you have any pre-existing conditions?**

Which of the following lung disease(s) do you have?	<input type="radio"/> Asthma <input type="radio"/> Chronic Obstructive Pulmonary Disease – COPD <input type="radio"/> Breathing disorders during sleep <input type="radio"/> Obstructive Sleep Apnea – OSAS <input type="radio"/> Interstitial Lung Disease <input type="radio"/> Lung Cancer <input type="radio"/> Other <input type="radio"/> None
What other lung diseases do you have?	<i>(Free text)</i>
Cardiovascular diseases (e.g. hypertension, stroke, etc.)	<input type="radio"/> No <input type="radio"/> Yes
Chronic kidney disease	<input type="radio"/> No <input type="radio"/> Yes
Diabetes	<input type="radio"/> No <input type="radio"/> Yes
Autoimmune Disease (e.g. Rheumatoid Arthritis, MS)	<input type="radio"/> No <input type="radio"/> Yes
HIV	<input type="radio"/> No <input type="radio"/> Yes
Overweight	<input type="radio"/> No <input type="radio"/> Yes
Other, please specify	<i>(Free text)</i>

## (B) Section: System Usability Scale (SUS)

"Evaluation of the performance of novel rapid diagnostics for SARS-CoV-2 at point-of-care"

### *System Usability Scale (SUS)*

© Digital Equipment Corporation, 1986

adapted format, version 1.0: 02/05/20

Name of the test: \_\_\_\_\_

User identifier and study site: \_\_\_\_\_ Date: \_\_\_\_\_

	Strongly disagree				Strongly agree
1. I think that I would like to use this system frequently	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
	1	2	3	4	5
2. I found the system unnecessarily complex	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
	1	2	3	4	5
3. I thought the system was easy to use	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
	1	2	3	4	5
4. I think that I would need the support of a technical person to be able to use this system	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
	1	2	3	4	5
5. I found the various functions in this system were well integrated	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
	1	2	3	4	5
6. I thought there was too much inconsistency in this system	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
	1	2	3	4	5
7. I would imagine that most people would learn to use this system very quickly	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
	1	2	3	4	5
8. I found the system very cumbersome to use	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
	1	2	3	4	5
9. I felt very confident using the system	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
	1	2	3	4	5
10. I needed to learn a lot of things before I could get going with this system	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
	1	2	3	4	5

### *Using SUS*

The SU scale is generally used after the respondent has had an opportunity to use the system being evaluated, but before any debriefing or discussion takes place. Respondents should be asked to record their immediate response to each item, rather than thinking about items for a long time.

All items should be checked. If a respondent feels that they cannot respond to a particular item, they should mark the center point of the scale.

## **(C) Section: Ease-of-Use Assessment (EoU)**

"Evaluation of the performance of novel rapid diagnostics for SARS-CoV-2 at point-of-care"

Thank you for your time to answer this questionnaire (about 20 minutes).

*Your input is very valuable!*

### **OVERALL QUESTIONS**

- 1. User identifier**
- 2. Date of filling the questionnaire**
- 3. In which country do you currently work?**
- 4. At which facility / study site do you currently work?**

*Mark only one oval.*

- Reilingen (Heidelberg)
- Berlin
- Liverpool
- Macae CTC
- Marica (Guapi)
- UFRJ

- 5. Which test are you assessing?**

*Mark only one oval.*

- Coris Bioconcept Respi Strip
- Bioeasy FIA
- Bioeasy Colloidal Gold
- SD Biosensor Standard F (Flourescence)
- SD Biosensor Standard Q
- Rapigen Biocredit Colloidal Gold

Abbott Panbio

LumiraDx

**6. Approximately how many times did you perform this test?**

*Mark only one oval.*

Only observed use

< 10

10 – 100

> 100

**7. Approximately how many times did you observe the use of this test (not performed yourself)?**

*Mark only one oval.*

< 10

10 – 50

50 – 100

> 100

**8. What is your profession?**

---

**9. How many years of laboratory experience do you have?**

---

**10. How many years of working experience in limited resource settings do you have?**

---

**11. How much experience do you have with interpreting the results of lateral flow tests or rapid diagnostics (e.g. for HIV, malaria, pregnancy)?**

Please note that we refer here to your experience with INTERPRETING the test results. If you do not conduct the test yourself, but do inform patients about the test results, we also consider that as experience with INTERPRETING the test results.

*Mark only one oval.*

- None
- < 1 year
- 1 – 3 years
- > 3 years

**TEST SPECIFIC QUESTIONS**

TRAINING

**12. How satisfied were you with the following components of the test training?**

*Mark only one oval per row.*

	Very satisfied	Satisfied	Neither	Dissatisfied	Very dissatisfied
Instructions for Use	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Standard Operating Procedures	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Face to face demonstration	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

**13. What additional materials (if any) do you think should be provided as part of the training?**

- None
- Other: \_\_\_\_\_

**14. How long should be the training of this test?**

*Mark only one oval.*

- Self-explanatory, no need for training
- 1 - 2 hours



2 - 4 hours

Half a day

Full day

**15. Do you consider proficiency testing necessary?**

Proficiency testing as in assessing the user's performance or ability to run the test following the training.

*Mark only one oval.*

Yes

No

Other: : \_\_\_\_\_

**16. Please comment here on the need for proficiency testing**

---

**17. Do you think that a company training is necessary?**

Yes

No

Other: : \_\_\_\_\_

**18. Please comment on having the company come to do an in-person training.**

---

**19. After how many of these tests do you feel you could perform the test on your own (having access to the training material)?**

*Mark only one oval.*

1 – 2 tests

3 – 5 tests

6 – 10 tests

> 10 tests

**ASSESSMENT OF TEST COMPONENTS**

**20. How satisfied are you with the quality of each of the components in the Test Strip Carton (in terms of ease of use and fit for purpose)?**

*Mark only one oval per row*

	Very satisfied	Satisfied	Neither	Dissatisfied	Very dissatisfied
External paper box of kit	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Extraction tube	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Filter cap	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Test cartridge / device	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Test cartridge packing / pouch	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

**21. Which kit component(s) should be improved in your opinion (if any)?**

*Please specify why and how*

---

**22. Overall, how satisfied are you with the kit components?**

*Mark only one oval.*

	1	2	3	4	5	
Very satisfied	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	Very dissatisfied

**23. How satisfied are you with the overall design of the test strip in terms of the following features?**

*Mark only one oval per row.*

	Very satisfied	Satisfied	Neither	Dissatisfied	Very dissatisfied
Size of test strip	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Size of the well to add sample mix	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

**24. How satisfied are you with the quality of the quality controls in terms of ease of use and fit for purpose?**

1            2            3            4            5

Very satisfied      Very dissatisfied

25. How useful do you find the inclusion of a positive quality control?

1 2 3 4 5

Very useful      Not useful

26. How useful do you find the inclusion of a negative quality control?

1 2 3 4 5

Very useful      Not useful

27. Please comment on the added value and quality of the quality controls.

---

28. How satisfied are you with the quality of the reader in terms of its ease of use and fit for purpose?

1 2 3 4 5

Very satisfied      Very dissatisfied

29. Overall, how satisfied are you with the reader?

1 2 3 4 5

Very satisfied      Very dissatisfied

30. Which component(s) of the reader (if applicable) should be improved in your opinion (if any)? Please specify why and how.

---

### ASSESSMENT OF TEST

31. Please determine the difficulty of the following steps:

Please consider your day-to-day/routine workload (or that of the people in the lab/area where this test could be implemented) to answer this question. Please leave any steps blank if not applicable.

*Mark only one oval per row.*

	Very easy	Easy	Neither	Difficult	Very difficult
a) Check expiry date	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

b) Label the extraction tube with patient identifier	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
c) Open the extraction tube by removing the seal	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
d) Insert the swab into the tube	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
e) Ease of swab extraction procedure	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
f) Ability to perform swab extraction procedure consistently	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
g) Ability to maintain cleanliness of ancillary devices (e.g. pipette) in order to avoid cross contamination	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
h) Remove the test cartridge from the pouch	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
i) Ease of transferring sample onto device	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
j) Ease of transferring exact quantity into the sample well	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
k) Ease of using instrument	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
l) Trouble shooting	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

**32. How satisfied are you with the logical sequence of steps?**

*Mark only one oval.*

	1	2	3	4	5	
Very satisfied	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	Very dissatisfied

**33. Overall, how difficult did you find the steps?**

*Mark only one oval.*

	1	2	3	4	5	
Very easy	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	Very difficult

**34. In general, how satisfied are you with the time relevant components (ex. are the steps relatively short, are there many specific timed steps that make it hard to keep track)?**

*Mark only one oval.*

	1	2	3	4	5	
Very satisfied	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	Very dissatisfied

**35. Please assess the time relevant components of the test.**

*Mark only one oval per row.*

	≤ 2 min	3 to 5 min	6 to 10 min	> 10 min
Pre analytic time (i.e. from when you get the swab to when you start incubation)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Incubation time (how long do you have to wait to get the results once you add your sample to the strip)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Analytic time (time needed to analyse the results)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

**36. In your opinion, about how many patients could be tested with this test in an 8-hour day (with one instrument and one sample method only)?**

*Mark only one oval per row.*

< 10

10 – 50

50 – 100

> 100

**37. Please comment here if you see any potential issues or room for improvement.**

---

**38. How did you find the results read-out in the following areas?**

*Mark only one oval per row.*

	Very easy	Easy	Neither	Difficult	Very difficult
a) Read-out from Reader	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
b) Interpretation of the test result	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

**39. Do you foresee any issues with reading these results considering the lighting conditions in the settings you currently work or have experience with?**

*Mark only one oval.*

- Yes (please explain below)
- No

**If yes, please explain here**

---

**OVERALL ASSESMENT**

**40. Overall, how did you find the use of this rapid COVID-19 diagnostic tool:**

*Mark only one oval.*

	1	2	3	4	5	
Very easy	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	Very difficult

**41. Please comment here on the use:**

---

**42. Which option(s) do you consider feasible in your setting?**

- Sequential testing (run tests one by one) ONLY
- Sequential testing AND batch testing (run multiple tests at the same time)

**43. Which aspect(s) of this test could cause difficulties in its day-to-day use? Tick all that apply.**

- Hands-on time
- Total assay time to result
- Batch processing
- Throughput
- Test results interpretation
- Overall number of steps
- Time sensitive steps
- Cartridge design
- Quality of material
- Training requirements
- Storage conditions and stability
- Waste management requirements
- I don't know
- None, I see no barriers for implementation

**44. Please give a short explanation for each of the aspects you selected above e.g. what could be the challenges in the day-to-day use:**

---

**SETTINGS OF USE**

**45. Do you see this test being used in its current form in your setting in your country?**

*Mark only one oval.*

Yes (please explain below)

No (please explain below)

I don't know

Please elaborate:

---

**46. If yes, at which health care level(s) do you see this test being implemented in your country**

*Tick all that apply.*

Family doctor / General physician

Peripheral hospital / lab

Reference hospital / lab

At a testing site operated by trainees staff without specific laboratory expertise

**47. If you don't see this test being used in its current form, which aspects should be changed to make it suitable for use in your setting in your country:**

---

**48. If you don't see this test being used in its current form, which aspects should be changed to make it suitable for use in your setting in low- and middle-income countries?**

---

**49. Anything else you would like to add?**

---

**THANK YOU VERY MUCH**

---



**(D) Figure 1: Matrix for Ease-of-Use Assessment**

Timestamp	green	green	green	yellow	yellow	amber	amber
1 User Identifier (first name, surname)	-	-	-	-	-	-	-
2 Date of filling the questionnaire	-	-	-	-	-	-	-
3 In which country do you currently work?	-	-	-	-	-	-	-
4 At which facility / study site do you currently work?	-	-	-	-	-	-	-
5 Which test are you assessing?	-	-	-	-	-	-	-
6 About how many times did you perform this test approximately?	-	-	-	-	-	-	-
7 About how many times did you observe the use of this test (not performed yourself)?	-	-	-	-	-	-	-
8 What is your profession?	-	-	-	-	-	-	-
9 How many years of laboratory experience do you have?	-	-	-	-	-	-	-
10 How many years of working experience in limited resource settings do you have?	-	-	-	-	-	-	-
11 How much experience do you have with interpreting the results of lateral flow tests or rapid diagnostics (e.g. for HIV, malaria, pregnancy)?	-	-	-	-	-	-	-
12 How satisfied were you with the following components of the test training? [Instructions for use]	very satisfied	satisfied	-	neither	-	dissatisfied	very dissatisfied
12 How satisfied were you with the following components of the test training? [Standard operating procedures]	-	-	-	-	-	-	-
12 How satisfied were you with the following components of the test training? [Face - to - face demonstration]	-	-	-	-	-	-	-
13 What additional materials (if any) do you think should be provided as part of the training?	None	-	-	1-2	-	>2	-
14 How long should the training of this test be?	Self - explanatory,	1 - 2 hours of train	2 - 4 hours	Half a day	-	Full Day	-
15 Do you consider proficiency testing necessary?	No	-	-	-	-	Yes	-
16 Please comment here on the need for proficiency testing:	-	-	-	-	-	-	-
17 Do you think that company training is necessary?	No	-	-	-	-	Yes	-
18 Please comment on having the company come to do an in-person training.	-	-	-	-	-	-	-
19 After how many of these tests do you feel you could perform the test on your own?	1 - 2 tests	-	-	3 - 5 tests	-	6 - 10 tests	10 tests
20 How satisfied are you with the quality of each of the components in the kit (in terms of ease of use and fit for purpose)? [External paper box of the kit]	very satisfied	satisfied	-	neither	-	dissatisfied	very dissatisfied
20 How satisfied are you with the quality of each of the components in the kit (in terms of ease of use and fit for purpose)? [Extraction tube]	very satisfied	satisfied	-	neither	-	dissatisfied	very dissatisfied
20 How satisfied are you with the quality of each of the components in the kit (in terms of ease of use and fit for purpose)? [Filter cap]	very satisfied	satisfied	-	neither	-	dissatisfied	very dissatisfied
20 How satisfied are you with the quality of each of the components in the kit (in terms of ease of use and fit for purpose)? [Test cartridge / device]	very satisfied	satisfied	-	neither	-	dissatisfied	very dissatisfied
20 How satisfied are you with the quality of each of the components in the kit (in terms of ease of use and fit for purpose)? [Test cartridge - packing pouch]	very satisfied	satisfied	-	neither	-	dissatisfied	very dissatisfied
20 How satisfied are you with the quality of each of the components in the kit (in terms of ease of use and fit for purpose)? [Swab for specimen collection]	very satisfied	satisfied	-	neither	-	dissatisfied	very dissatisfied
21 Which kit component(s) should be improved in your opinion (if any)?	-	-	-	-	-	-	-
22 Overall, how satisfied are you with the kit components?	1	2	-	3	-	4	5
23 How satisfied are you with the design of the following features? [Size of the cartridge]	very satisfied	satisfied	-	neither	-	dissatisfied	very dissatisfied
23 How satisfied are you with the design of the following features? [Size of the well to add sample mix]	very satisfied	satisfied	-	neither	-	dissatisfied	very dissatisfied
24 How satisfied are you with the quality of the quality controls in terms of ease of use and fit for purpose	1	2	-	3	-	4	5
25 How useful do you find the inclusion of a positive control?	1	2	-	3	-	4	5
26 How useful do you find the inclusion of a negative control?	1	2	-	3	-	4	5
27 Please comment on the added value and quality of the quality controls.	-	-	-	-	-	-	-
28 How satisfied are you with the quality of the reader in terms of its ease of use and fit for purpose?	1	2	-	3	-	4	5
29 Overall, how satisfied are you with the Lumira instrument?	1	2	-	3	-	4	5
30 Which component(s) of the Lumira instrument should be improved in your opinion (if any) and why?	-	-	-	-	-	-	-
31 Please determine the difficulty of the following steps: [a] Check expiry date]	Very easy	Easy	-	Neither	-	Difficult	Very difficult
31 Please determine the difficulty of the following steps: [b] Label the assay diluent tube with the patient identifier]	Very easy	Easy	-	Neither	-	Difficult	Very difficult
31 Please determine the difficulty of the following steps: [c] Open the extraction tube by removing the seal (if appl.)]	Very easy	Easy	-	Neither	-	Difficult	Very difficult
31 Please determine the difficulty of the following steps: [d] Insert the swab into the tube]	Very easy	Easy	-	Neither	-	Difficult	Very difficult
31 Please determine the difficulty of the following steps: [e] Ease of swab extraction procedure]	Very easy	Easy	-	Neither	-	Difficult	Very difficult
31 Please determine the difficulty of the following steps: [f] Ability to perform extraction procedure consistently]	Very easy	Easy	-	Neither	-	Difficult	Very difficult
31 Please determine the difficulty of the following steps: [g] Ability to maintain cleanliness of ancillary devices (e.g. pipette) in order to avoid cross-contamination]	Very easy	Easy	-	Neither	-	Difficult	Very difficult
31 Please determine the difficulty of the following steps: [h] Remove the test cartridge from the pouch]	Very easy	Easy	-	Neither	-	Difficult	Very difficult
31 Please determine the difficulty of the following steps: [i] Ease of transferring sample onto device]	Very easy	Easy	-	Neither	-	Difficult	Very difficult

31 Please determine the difficulty of the following steps: (j) Ease of transferring sample onto device]	Very easy	Easy	-	Neither	-	Difficult	Very difficult
31 Please determine the difficulty of the following steps: (j) Ease of transferring exact quantity into the sample well]	Very easy	Easy	-	Neither	-	Difficult	Very difficult
31 Please determine the difficulty of the following steps: (k) Ease of using the LumiraDx instrument]	Very easy	Easy	-	Neither	-	Difficult	Very difficult
31 Please determine the difficulty of the following steps: (l) Trouble shooting]	Very easy	Easy	-	Neither	-	Difficult	Very difficult
32 How satisfied are you with the logical sequence of steps?	1	2	-	3	-	4	5
33 Overall, how difficult did you find the steps?	1	2	-	3	-	4	5
34 Overall how satisfied are you with the time-relevant components (e.g. are the steps relatively long, are there many specific timed steps that make it hard to keep track of)?	1	2	-	3	-	4	5
35 Please assess the time relevant components of the test. [Pre-analytic time (i.e. from when you get the swab to when you start incubation)]	2 min	-	-	3 to 5 min	6 to 10 min	10 min	-
35 Please assess the time relevant components of the test. [Incubation time (i.e. how long do you have to wait to get the results once you add your sample to the strip)]	15 min	15 to 30 min	-	30 to 60 min	-	60 min	-
35 Please assess the time relevant components of the test. [Analytic time (i.e. time needed to analyse the results once the test conduction is completed)]	2 min	-	-	3 to 5 min	6 to 10 min	10 min	-
36 In your opinion, about how many patients could be tested with this test in an 8-hour day?	100	-	-	50 - 100	-	10 - 50	10
37 Please comment here if you see any potential issues or room for improvement.	-	-	-	-	-	-	-
38 How did you find the results read-out in the following areas: (a) Read-out from Reader]	Very easy	Easy	-	Neither	-	Difficult	Very difficult
38 How did you find the results read-out in the following areas: (b) Interpretation of the test result]	Very easy	Easy	-	Neither	-	Difficult	Very difficult
39 Do you foresee any issues with reading these results considering the lighting conditions in the settings you currently work or have experience with?	No	-	-	-	-	-	Yes (please explain below)
39 If yes, please explain here	-	-	-	-	-	-	-
40 Overall, how did you find the use of this rapid COVID-19 diagnostic tool?	1	2	-	3	-	4	5
41 Please comment here on the use:	-	-	-	-	-	-	-
42 Which option(s) do you consider feasible in your setting (assuming you only have one instrument and one sampling method)?	Sequential testing	-	-	-	-	Sequential testing	-
43 Which aspect(s) of this test could cause difficulties in its day-to-day use?	0	-	-	1	2	3	4
44 Please give a short explanation for each of the aspects you selected above e.g. what could be the challenges in the day-to-day use:	-	-	-	-	-	-	-
45 Do you see this test being used in its current form in your setting in your country?	Yes	-	-	-	-	No	-
45 Please elaborate:	-	-	-	-	-	-	-
46 If yes, at which health care level(s) do you see this test being implemented in your country?	At a testing site of none	Family doctor / General practice	-	Peripheral hospital	-	Reference hospital	None
47 If you don't see this test being used in its current form, which aspects should be changed to make it suitable for use in your setting in your country:	none	-	-	1-2	-	>2	-
48 Do you see this test being used in its current form in your setting in low and middle income countries?	Yes (please explain)	-	-	-	-	No (please explain)	-
48 Please elaborate:	-	-	-	-	-	-	-
49 At which health care level(s) do you see this test being implemented in low and middle income countries?	Primary health care	Family doctor / General practice	Health centre / mid-level	District hospital /	-	Reference hospital	None
50 If you don't see this test being used in its current form, which aspects should be changed to make it suitable for use in your setting in low and middle income countries?	none	-	-	1	2	3	4
52 Anything else you would like to add?	-	-	-	-	-	-	-

**(E) Table 1: Detailed list of symptoms for all PCR positives**

Viral load ( $\log_{10}$ RNA copies/mL)	Result Ag-RDT	Increased temperature/fever	Cough	Do you have a productive cough?	Sore throat	Shortness of breath	Muscle pain/Body aches	Fatigue	Headache	Runny nose	Chest pain	Diarrhea	Nausea/vomiting	Loss of taste /smell	Other symptoms
6.85	positive	No	Yes	Yes	No	No	No	Yes	Yes	Yes	No	No	No	Yes	
7.56	positive	No	Yes	No	Yes	No	Yes	Yes	Yes	Yes	No	No	No	Yes	No
7.97	positive	Yes	Yes	No	Yes	No	Yes	Yes	Yes	Yes	No	No	No	Yes	Yes
7.76	positive	No	No	No	Yes	Yes	Yes	Yes	Yes	No	Yes	No	No	No	No
8.00	positive	Yes	Yes	No	No	No	Yes	Yes	Yes	No	Yes	No	No	No	Yes
7.61	positive	Yes	Yes	Yes	No	No	Yes	Yes	No	No	No	No	No	No	No
7.11	negative	No	No	No	No	No	No	No	No	No	No	No	No	Yes	No
8.15	positive	Yes	Yes	No	Yes	No	Yes	No	Yes	Yes	No	No	No	Yes	No
6.82	positive														
5.99	positive	Yes	No	No	No	No	Yes	Yes	No	No	No	No	No	No	No
7.79	positive	No	Yes	No	Yes	No	Yes	No	Yes	No	No	No	No	No	No
3.99	positive	No	No	No	No	Yes	No	Yes	Yes	No	No	No	No	No	No
6.32	positive	No	Yes	Yes	No	No	Yes	Yes	Yes	Yes	No	No	No	No	No
8.38	positive	No	Yes		Yes	No	Yes	Yes	Yes	Yes	No	No	No	No	No
4.26	negative	No	No	No	No	No	Yes	Yes	No	No	No	No	No	No	Yes
7.73	positive	No	No	No	No	No	Yes	Yes	Yes	No	No	No	No	Yes	Yes
8.48	positive	No	Yes	No	Yes	No	No	Yes	Yes	Yes	No	No	No	Yes	No
8.20	positive	Yes	Yes	No	No	Yes	Yes	Yes	Yes	Yes	No	Yes	No	Yes	No
8.48	positive	No	Yes	No	No	Yes	Yes	Yes	No	Yes	No	No	No	Yes	No
8.32	positive	Yes	Yes	Yes	No	No	Yes	No	Yes	Yes	No	No	No	No	No
6.18	positive	Yes	No	No	No	No	No	Yes	No	Yes	No	No	No	Yes	Yes
3.78	negative	No	Yes	No	Yes	No	No	No	No	Yes	No	No	No	Yes	No
7.61	positive														
5.56	positive		Yes	No	No	No	Yes	Yes	Yes	Yes	No	No	No	Yes	No
3.99	positive														
7.73	positive	Yes	Yes	No	Yes	No	Yes	Yes	Yes	No	Yes	Yes	No	No	No
8.08	positive	No	No	No	No	No	Yes	Yes	Yes	No	No	Yes	No	No	No

7.53	positive	Yes	Yes	No	Yes	No	Yes	Yes	Yes	Yes	No	Yes	No	Yes	No
7.56	positive	No	Yes	No	Yes	No	No	No	Yes	Yes	No	No	No	No	No
7.83	positive	Yes	No	No	No	No	Yes	Yes	Yes	No	No	No	No	No	No
6.67	positive														
6.58	positive	No	Yes	No	No	No	Yes	Yes	Yes	No	Yes	Yes	No	No	No
4.90	positive	Yes	No	No	Yes	No	No	No	Yes	No	No	No	No	No	No
5.40	positive	No	Yes	No	Yes	No	No	Yes	Yes	No	No	No	Yes	No	No
2.95	negative														
8.59	positive	Yes	Yes	Yes	No	No	Yes	No	No	Yes	No	No	No	No	No
6.04	positive	Yes													
4.81	negative	No	Yes	No	No	No	No	Yes	Yes	No	No	No	No	Yes	
8.08	positive	No	Yes	No	No	No	No	Yes	No	No	No	No	No	No	No
7.41	positive	Yes	No	No	No	No	Yes	Yes	Yes	No	No	Yes	No	No	No
8.00	positive	No	No	No	Yes	No	No	No	No	Yes	No	No	No	No	No
4.79	positive	Yes	Yes	Yes	No	No	Yes	Yes	Yes	No	No	Yes	No	No	No
6.94	positive	Yes	No	Yes	No	No	Yes	Yes	No	Yes	No	No	No	Yes	
5.52	positive	No	No	No	No	No	Yes	Yes	Yes	No	No	Yes	No	No	No
7.04	positive	No	No	No	Yes	No	Yes	Yes	Yes	No	No	No	No	Yes	No
6.28	positive														
8.11	positive	No	Yes	Yes	No	No	No	Yes	No	Yes	No	No	No	Yes	No
5.11	positive	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	No	No	Yes	No
7.71	positive	Yes	Yes	No	Yes	No	Yes	Yes	Yes	Yes	No	No	No	No	No
3.66	negative	Yes	Yes	No	Yes	No	No	Yes	Yes	No	No	Yes	No	Yes	Yes
6.82	positive														
7.15	positive	No	No	No	No	No	No	No	No	Yes	No	No	No	No	No
7.85	positive	No	No	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	No	No	No
6.97	positive	No	Yes	No	Yes	No	No	Yes	Yes	No	Yes	No	No	Yes	No
2.60	negative	No	Yes	No	Yes	Yes	No	Yes	Yes	No	No	No	No	No	Yes
4.08	negative														
8.80	positive	No	Yes		Yes		Yes	Yes	Yes	Yes	No	No	No	No	No
6.61	negative	No	Yes	No	No	No	No	Yes	Yes	No	No	No	No	No	Yes
4.36	positive	No	No	No	Yes	No	No	Yes	No	No	No	No	No	Yes	No
4.18	negative	No	No	No	No	Yes	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes
5.38	positive														

6.04	positive	No	No	No	No	No	No	No	No	Yes	No	No	No	No	No
7.08	positive	No	Yes	No	No	No	No	No	No	No	No	No	No	No	No
7.45	positive	Yes	Yes	Yes	No	No	No	Yes	Yes	No	No	No	No	No	No
4.26	positive	No	Yes	Yes	No	No	Yes	Yes	Yes	No	No	No	Yes	Yes	No
7.79	positive	No	Yes	Yes	No	No	No	No	Yes	No	Yes	No	No	No	No
6.07	negative	No	No	No	No	No	No	Yes	No	No	No	No	No	Yes	No
8.25	positive	No	Yes	Yes	No	No	Yes		Yes	Yes	No	No	No	No	No
7.07	positive	No	Yes	No	No	No	Yes	Yes	No	Yes	No	No	Yes	No	No
9.34	positive	No	Yes	Yes	No	No	Yes	No	No	Yes	No	No	No	No	No
9.08	positive	No	Yes	No	No	No	No	Yes	No	Yes	No	Yes	No	No	No
7.28	positive	No	No	No	Yes	No	Yes	Yes	Yes	Yes	No	No	No	Yes	No
7.53	positive	No	Yes	No	Yes	No	Yes	Yes	Yes	Yes	No	No	Yes		No
5.47	positive	No	Yes	No	Yes	No	No	No	No	Yes	No	No	No	No	No
9.03	positive	Yes	No	No	No	No	No	Yes	No	No	No	No		No	No
8.99	positive	Yes	Yes	No	No	No	Yes	Yes	No	Yes	No	No	No	No	No
8.61	positive	No	Yes	No	Yes	No	Yes	No	No	No	No	No	No	No	No
8.12	positive	No	No	No	Yes	Yes	No	No	Yes	No	No	No	No	Yes	No
9.37	positive	No	Yes	No	No	No	No	No	Yes	Yes	No	No	No	No	Yes
6.58	positive	No	Yes	No	Yes	No	Yes	Yes	No	No	No	No	No	Yes	No
6.19	positive	No	No	No	No	No	Yes	Yes	Yes	Yes	Yes	No	Yes	Yes	No
6.93	positive	No	No	No	No	No	No	Yes	No	Yes	No	No	No	Yes	No
4.94	negative	No	No	No	Yes	No	No	No	No	No	No	No	No	No	No
9.43	positive	Yes	Yes	No	Yes	No	Yes	Yes	Yes	No	No	No	No	No	No
5.04	negative	No	Yes	No	No	No	No	Yes	No	No	No	No	No	Yes	No
9.30	negative	No	No	No	Yes	No	No	Yes	No	No	No	No	No	No	No
8.77	positive	Yes	Yes	No	No	Yes	Yes	Yes	No	Yes	No	No	No	No	No
8.10	positive	No	Yes	No	No	No	No	No	No	Yes	No	No	No	No	No
9.29	positive	No	Yes	No	No	No	No	Yes	No	No	No	No	No	No	No
6.97	negative	No	No	No	No	No	No	No	No	No	No	No	No	Yes	No
4.94	positive	No	No	No	No	No	No	Yes	No	Yes	No	No	No	Yes	No
8.14	positive	Yes	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	No	Yes	No	Yes	No
5.61	positive	Yes	Yes	No	No	No	No	Yes	No	No	No	No	No	No	No
6.94	positive	No	No	No	No	No	No	No	No	Yes	No	No	No	Yes	No
7.07	positive	No	No	No	No	No	No	No	No	No	No	No	No	Yes	No

5.76	positive	No	No	No	No	No	No	No	No	No	No	No	No	Yes	No
5.68	positive	No	No	No	No	No	No	Yes	No	No	No	No	No	Yes	No
8.56	positive	Yes	No	No	No	No	No	Yes	No	No	No	No	No	No	No
5.42	negative	No	No	No	No	No	No	No	No	No	No	No	No	Yes	No
6.80	positive	No	Yes	No	No	No	No	Yes	No	No	No	No	No	Yes	No
5.95	positive	No	No	No	No	No	Yes	Yes	No	Yes	No	No	No	Yes	No
3.72	negative	No	Yes	No	No	No	No	No	Yes	No	No	No	No	Yes	No
3.57	negative	No	No	No	No	No	No	No	No	No	No	No	No	Yes	No
6.23	negative	No	Yes	No	No	No	No	Yes	No	Yes	No	No	No	Yes	No
6.87	positive	No	No	No	No	No	No	No	Yes	No	No	No	No	Yes	No
8.08	negative	No	Yes	No	No	No	Yes	Yes	No	No	No	No	No	No	No
6.95	positive	No	No	No	Yes	No	No	No	No	No	No	No	No	No	No
5.88	positive	No	Yes	Yes	No	No	No	No	No	No	No	No	No	Yes	No
6.81	positive	No	No	No	No	No	No	No	No	Yes	No	No	No	No	No
8.65	positive	No	No	No	No	No	Yes	Yes	No	Yes	No	No	No	No	No
6.83	positive	No	No	No	Yes	No	No	Yes	Yes	No	No	No	No	Yes	No
8.64	positive	No	Yes	No	Yes	No	Yes	Yes	Yes	No	No	No	No	Yes	No
7.85	positive	No	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	No	Yes	No	No	No
8.32	positive	No	No	No	Yes	No	Yes	Yes	Yes	No	No	No		No	No
9.27	negative	No	Yes		Yes	No	No	Yes	Yes	No	No	No		No	No
8.89	positive	Yes	Yes	Yes	Yes	No	Yes	No	Yes	Yes	No	Yes	No	Yes	No
4.46	positive	Yes	No	No	Yes	No	No	Yes	Yes	No	No	Yes	No	Yes	No
6.58	positive	No	No	No	Yes	No	No	No	No	No	No	No	No	Yes	No
7.75	negative	No	Yes	No	No	No	Yes	Yes	Yes	Yes	No	No	No	No	No
9.69	positive	Yes	No	No	No	No	Yes	Yes	No	No	No	No	No	Yes	
8.91	positive	No	Yes	No	Yes	No	Yes	Yes	Yes	No	No	Yes	No	Yes	No
8.70	positive	Yes	Yes	Yes	No	No	No	No	Yes	No	No	No	No	No	No
8.17	positive	No	Yes		No	No	No	Yes	No	No	No	No	No	No	No
8.72	positive	No	Yes	No	No	No	No	No	No	No	No	No	No	Yes	No
3.83	negative	No	No	No	Yes	No	No	No	No	No	No	No	No	No	No
7.86	positive	No	Yes	No	Yes	No	Yes	Yes	Yes	Yes	No	No	No	Yes	No
8.75	positive	No	No	No	No	No	Yes	No	No	No	No	No	No	No	No
7.82	positive	No	Yes	Yes	No	No	No	Yes	Yes	No	No	Yes	No	No	No
8.01	positive	No	No	No	Yes	No	No	No	No	Yes	No	No	No	Yes	No

9.08	positive	No	Yes	No	No	No	Yes	No	Yes	No	No	No	No	No	Yes
9.63	positive	No	No	No	No	No	No	Yes	No	Yes	No	No	No	No	No
7.47	positive	No	Yes	Yes	No	No	Yes	Yes	Yes	Yes	No	Yes	Yes	No	No
7.24	positive	No	No	No	No	No	Yes	No	Yes	Yes	No	No	No	Yes	No
8.67	positive	Yes	Yes	No	No	No	Yes	Yes	Yes	Yes	No	No	No	Yes	No
8.47	positive	Yes	No	Yes	No	No	Yes	Yes	Yes	No	No	No	No	No	No
6.03	negative	No	No	No	No	No	No	Yes	Yes	No	No	No	No	Yes	No
5.86	negative	Yes	No	No	No	No	Yes	Yes	Yes	No	No	No	No	Yes	No
6.81	positive	No	Yes	Yes	Yes	No	Yes	Yes	Yes	Yes	No	No	No	Yes	No
4.70	negative	No	Yes	No	No	No	No	No	No	No	No	No		Yes	
6.61	positive	No	Yes		No	No	No	No	No	Yes	No	No		Yes	No
7.34	positive						Yes							Yes	
8.26	positive	No	Yes	Yes	Yes	No	No	Yes	No	No	No	No	No	Yes	No
5.61	positive	No	Yes	No	No	No	No	No	Yes	No	No	No	No	Yes	No
9.00	positive	Yes	No	No	No	No	No	Yes	No	Yes	No	No	No	Yes	No
8.38	positive	Yes	No	No	No	No	No	No	No	No	No	No	No	No	Yes
9.19	positive	No	No	No	Yes	No	Yes	Yes	Yes	No	Yes	No	No	Yes	No

**(F) Table 2: Antigen-based RDT with test result, CT values and viral load for PCR positive participants in Berlin and Heidelberg**

CT-value reported here represent the E-gene genome target (similar to the target described by Corman) in descending order. A conversion of CT-values for RT-PCR tests into viral-load was performed using quantified specific in vitro-transcribed RNA (Corman 2020 Eurosurveillance).

Berlin			
Antigen RDT result	CT-value (E-Gene)	Viral load (log <sub>10</sub> SARS-CoV2 RNA copies /mL)	PCR assay
positive	14.61	9.63	TIB Molbiol
positive	15.29	9.43	TIB Molbiol
positive	15.51	9.37	TIB Molbiol
positive	15.60	9.34	TIB Molbiol
negative	15.74	9.30	TIB Molbiol
positive	15.76	9.29	TIB Molbiol
negative	15.84	9.27	TIB Molbiol
positive	16.09	9.19	TIB Molbiol
positive	16.46	9.08	TIB Molbiol
positive	16.64	9.03	TIB Molbiol
positive	16.76	9.00	TIB Molbiol




positive	17.12	8.89	TIB Molbiol
positive	17.53	8.77	TIB Molbiol
positive	17.60	8.75	TIB Molbiol
positive	17.69	8.72	TIB Molbiol
positive	17.75	8.70	TIB Molbiol
positive	17.85	8.67	TIB Molbiol
positive	17.93	8.65	TIB Molbiol
positive	18.04	8.61	TIB Molbiol
positive	18.82	8.38	TIB Molbiol
positive	19.04	8.32	TIB Molbiol
positive	19.23	8.26	TIB Molbiol
positive	19.27	8.25	TIB Molbiol
positive	19.63	8.14	TIB Molbiol
positive	19.70	8.12	TIB Molbiol
positive	19.77	8.10	TIB Molbiol
negative	19.85	8.08	TIB Molbiol
positive	20.08	8.01	TIB Molbiol
positive	20.58	7.86	TIB Molbiol
positive	21.88	7.47	TIB Molbiol
positive	22.34	7.34	TIB Molbiol

positive	22.52	7.28	TIB Molbiol
positive	22.66	7.24	TIB Molbiol
positive	23.25	7.07	TIB Molbiol
negative	23.57	6.97	TIB Molbiol
positive	23.65	6.95	TIB Molbiol
positive	23.69	6.94	TIB Molbiol
positive	23.91	6.87	TIB Molbiol
positive	24.10	6.81	TIB Molbiol
positive	24.11	6.81	TIB Molbiol
positive	24.15	6.80	TIB Molbiol
positive	24.78	6.61	TIB Molbiol
negative	26.07	6.23	TIB Molbiol
negative	26.61	6.07	TIB Molbiol
positive	26.99	5.95	TIB Molbiol
positive	27.23	5.88	TIB Molbiol
negative	27.30	5.86	TIB Molbiol
positive	28.14	5.61	TIB Molbiol
positive	28.16	5.61	TIB Molbiol
positive	28.62	5.47	TIB Molbiol
negative	28.78	5.42	TIB Molbiol

negative	31.20	4.70	TIB Molbiol
negative	34.14	3.83	TIB Molbiol
negative	34.50	3.72	TIB Molbiol
negative	35.00	3.57	TIB Molbiol

**(G) Figure 2: Correlation between the cut-off-index value and the viral load for all RT-PCR positive cases**



**(H) Table 3: Discrepant analysis**

PCR	Ag-Test Lumira	COI	CT value: E-Gene	Viral load	Buffer PCR	Buffer CT value: E-Gene	Buffer Viral load
positive	negative		22,47	7,11			
positive	negative		32,18	4,26			
positive	negative		33,83	3,78			
positive	negative		36,61	2,95	negative		
positive	negative		30,25	4,81	negative		
positive	negative		34,16	3,66	negative		
positive	negative	284	37,82	2,6	negative		
positive	negative	330	32,75	4,08	negative		
positive	negative	168	24,21	6,61	negative		
positive	negative	199	32,46	4,18	negative		
positive	negative		26,61	6,07			
positive	negative	546	33,55	4,94			
positive	negative		33,21	5,04			
positive	negative		15,74	9,3	positive	34,9	4,52
positive	negative	251	23,57	6,97			
positive	negative	575	28,78	5,42			
positive	negative	303	34,5	3,72			
positive	negative	194	35	3,57			
positive	negative	379	26,07	6,23			
positive	negative	218	19,85	8,08			
positive	negative		15,84	9,27	positive		< 100 CP/mL
positive	negative		24,05	7,75	positive	37,82	2,61
positive	negative	168	34,14	3,83			
positive	negative	252	29,87	6,03			
positive	negative	268	27,03	5,86			
positive	negative	186	31,2	4,7			

negative	positive				negative		
negative	positive				negative		
negative	positive				negative		
negative	positive	687					

**(I) Table 4: Exclusivity testing of LumiraDx™**

Pathogen	CT (lowest - highest value) concentration (colony forming units [CFU] /ml)	LumiraDx™	Cross-Reactivity
Coronavirus OC 43 Coronavirus NL 63 Coronavirus 229 E Coronavirus HKU 1	19.8 - 27.7 25.9 - 30.6 22.7 - 27.0 18.1 - 31.5	3/3 negative 3/3 negative 3/3 negative 3/3 negative	no
Adenovirus	26.7 - 35	5/5 negative	no
Bocavirus	31.5 - 33.2	2/2 negative	no
Influenza A H3N2 virus Influenza A H1N1 virus Influenza B virus	17.6 - 30.7 19.4 - 29.9 16.8 - 30.5	4/4 negative 3/3 negative 3/3 negative	no
Metapneumovirus	26.2 - 32.7	4/4 negative	no
Parainfluenza virus	17.4 - 32.5	10/10 negative	no
Respiratory syncytial virus	16.4 - 31.2	10/10 negative	no
Rhinovirus	28.5 - 35	10/10 negative	no
<i>Mycoplasma pneumoniae</i>	23.2 - 35	8/8 negative	no
<i>Staphylococcus aureus</i>	Unknown (clinical samples)	9/9 negative	no
<i>Streptococcus sp.</i>	1x10 <sup>7</sup> KBE/ml	7/7 negative	no

**(J) Figure 3: System Usability Score and Ease-of-Use assessment results**

Ease of Use Assessment		
2019-Novel Coronavirus (2019-nCoV) Antigen Rapid Test Kit by LumiraDx		
Over-view	Overall rating	On a system usability scale, the test scored <b>65 out of 100</b> points.
	Major difficulties in day-to-day use	Difficulties could mainly occur due to the test's low throughput and the difficulty of doing batch testing.
Quality of the test's hardware	External paper box of the kit	
	Extraction tube	
	Filter cap	
	Test cartridge/device/strip	
	Test cartridge/device/strip - packing pouch	
	Quality controls	
	Reader	
	Overall quality of kit components	
	Size of the cartridge/device/strip	
	Size of the well to add sample mix	
	inclusion of control	Positive control
Negative control		
Test Prep	Instructions for use	
	Required training	
	Company training required *	
	Required test runs	
Ease of test execution	Check expiry date	
	Label the extraction tube with the patient identifier	
	Open the assay extraction tube by removing the seal	
	Insert the swab into the tube	
	Swab extraction procedure	
	Perform extraction procedure consistently	
	Maintain cleanliness of ancillary devices	
	Remove the test cartridge/device/strip from the pouch	
	Transferring sample onto device	
	Transferring exact quantity into the sample well	
	Trouble shooting	
Logical sequence of steps		
Overall difficulty of steps		
Procedure time	Pre-analytic time	
	Incubation time	
	Analytic time	
	8-hour throughput	
Ease of result interpretation	Issues with lighting	
	Read-out from reader	
	Interpretation of the test result	
	Reader's ease of use	
Fields of application	Overall satisfaction with the reader	
	Batch testing possible	
	Usability in high income countries	
Storage conditions	Range of health care levels (high income countries)	
	Stability of test	
	Stability of control material	
	Storage temperature of test	
Storage temperature of control material		

\* satisfactory means no company training required

Legend	
N/A	Not applicable
	Satisfactory
	Average
	Dissatisfactory



**(K) Table 5: Comorbidities and list of symptoms of participants overall, Berlin and Heidelberg**

	Overall	Heidelberg	Berlin
<b>Data combined: Overweight and Adipositas &gt; BMI 25 – Information available on N=703</b>			
Yes	327 (46.5%)	243 (50.2%)	84 (38.4%)
No	376 (53.5%)	241 (49.8%)	135 (61.6%)
<b>Comorbidities – Information available on N=760</b>			
All with comorbidities	241	183	58
<b>Lung diseases</b>			
Asthma bronchiale	60	39	21
Chronic obstructive pulmonary disease (COPD)	7	5	2
Breathing disorders during sleep and obstructive Sleep Apnea (OSAS)	9	9	0
Interstitial Lung Disease	0	0	0
Lung Cancer	2	1	1
Other	13	11	2
<b>Other diseases</b>			
Cardiovascular diseases	80	63	17
Chronic kidney diseases	9	8	1
Autoimmune	51	48	3
HIV	1	1	0
Others	79	52	27
<b>List of symptoms reported</b>			
Fever	90 (19.0%)	49 (23.3%)	41 (15.5%)
Fever measured			
a. <38.4	52(74.3%)	37(82.2%)	15(60%)
b. >38.5 and <=39.4	17(24.3%)	8(17.8%)	9(36%)
c. >39.5 and >40.5	1 (1.4%)	0	1(4%)
Cough	247 (51.6%)	112 (52.6%)	135 (50.8%)
Productive cough	72 (15.5%)	40 (18.9%)	32 (12.6%)
Sore throat	242 (50.2%)	115 (53.5%)	127 (47.6%)
Shortness of breath	46 (9.7%)	31 (14.8%)	15 (5.7%)
Muscle pain	176 (36.7%)	81 (38.2%)	95 (35.4%)
Fatigue	297 (62.0%)	143 (66.8%)	154 (58.1%)
Headache	251 (52.3%)	130 (60.7%)	121 (45.5%)
Runny nose	197 (41.5%)	87 (41.6%)	110 (41.4%)
Chest pain	41	35	6

	(8.6%)	(16.6%)	(2.3%)
Diarrhea	54 (11.3%)	25 (11.8%)	29 (10.8%)
Nausea	25 (5.4%)	16 (4.3%)	9 (6.3%)
Loss of taste and smell	104 (21.8%)	32 (15.3%)	72 (27.0%)

**(L) Table 6: Sensitivity and Specificity overall and by subgroups**

	Overall N	Ag-Test positive/ PCR positive N (%)	Ag-Test negative/ PCR positive N (%)	Ag-Test positive/ PCR negative N (%)	Ag-Test negative/ PCR negative N (%)	Sensitivity % (95% CI)	Specificity % (95% CI)
<b>Sensitivity</b>							
<b>Overall</b>	761	120 (15.8)	26 (3.4)	4 (0.5)	611 (79.7)	82.2 (75.2-87.5)	99.3 (98.3-99.7)
<b>Heidelberg</b>	488	55 (11.3)	10 (2.0)	3 (0.6)	420 (86.1)	84.6 (73.9-91.4)	99.3 (97.9-99.8)
<b>Berlin</b>	273	65 (23.8)	16 (5.9)	1 (0.4)	191 (70.0)	80.2 (70.3-87.5)	99.5 (97.1-100)
<b>Symptom duration – Information available for N=472</b>							
<b>0-7 days Overall</b>	423	102 (24.1)	16 (3.8)	2 (0.5)	303 (71.6)	86.4 (79.1-91.5)	99.3 (97.6-99.8)
<b>8-14 days Overall</b>	39	7 (17.9)	6 (15.4)	0	26 (66.7)	53.8 (29.1-76.8)	100 (87.1-100)
<b>Symptomatic versus Asymptomatic – Information available for N= 472</b>							
<b>Symptomatic</b>	210	45 (21.4)	8 (3.8)	2 (1.0)	155 (73.8)	84.9 (72.9-92.1)	98.7 (95.5-99.6)
<b>Asymptomatic</b>	271	7 (2.6)	2 (0.7)	1 (0.4)	261 (96.3)	77.8 (45.3-93.7)	99.6 (97.9-100)
<b>CT-Value PCR &lt;30 and &gt;=30 – Information available for N=146</b>							
<b>CT value PCR &lt;30</b>	122	110	12	NA	NA	90.2 (83.6-94.3)	NA
<b>CT value PCR ≥30</b>	24	10	14	NA	NA	41.7 (24.5-61.2)	NA
<b>CT-Value PCR &lt;25 and &gt;=25 – Information available for N=146</b>							
<b>CT value PCR &lt;25</b>	95	88	7	NA	NA	92.6 (85.6-96.4)	NA
<b>CT value PCR ≥25</b>	51	32	19	NA	NA	62.7 (49.0-74.7)	NA